A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arkansas 85032-2181, United States
Aurora, Colorado 80045, United States
Miami, Florida 33136, United States
St Louis, Missouri 63110, United States
New York, New York 10021, United States
Patchogue, New York 11772, United States
Columbus, Ohio 43221, United States
Oklahoma City, Oklahoma 73104, United States
Philadelphia, Pennsylvania 19104, United States
Fitzroy, Victoria 3065, Australia
Innsbruck, 6020, Austria
Salzburg, 5020, Austria
Rio de Janeiro, Rio de Janeiro 21941-913, Brazil
Vancouver, British Columbia V6T 1Z3, Canada
Bron, 69677, France
Clermont-Ferrand, 63003, France
Berg, 82335, Germany
Dresden, 01307, Germany
Frankfurt am Main, 60528, Germany
Szeged, 6725, Hungary
Orbassano, Piedmont 10043, Italy
Mexico City, Mexico CITY (federal District) 14390, Mexico
Sittard-Geleen, 6162 BG, Netherlands
Lodz, 90-153, Poland
Lublin, 20-954, Poland
Timi?oara, 300595, Romania
Kazan', Tatarstan Republic 420103, Russia
Santiago de Compostela, LA Coruña 15706, Spain
Chernivtsi, Chernihiv Governorate 58022, Ukraine
Odesa, Kherson Governorate 65025, Ukraine
Kyiv, KIEV Governorate 04107, Ukraine
Dnipropetrovsk, 49027, Ukraine
Liverpool, L9 7LJ, United Kingdom